thiophenes has been researched along with etidronate in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 14 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barton, IP; Boonen, S; Laan, RF; Watts, NB | 1 |
| Briot, K; Roux, C; Thomas, T; Trémollières, F | 1 |
| Díaz-Curiel, M; Moro Alvarez, MJ | 1 |
| Rizzoli, R | 1 |
| Alva, D; Cesareo, R; Contini, S; De Rosa, B; Iozzino, M; Lauria, A; Mallardo, L; Napolitano, C; Orsini, A; Reda, G | 1 |
| Bruyère, O; Burlet, N; Cooper, C; Delmas, PD; Reginster, JY; Rizzoli, R | 1 |
| Foo, AC; Glendenning, P; Inderjeeth, CA; Lai, MM | 1 |
| Bruyère, O; Hiligsmann, M; Reginster, JY | 1 |
| Bolland, MJ; Gamble, GD; Grey, AB; Reid, IR | 1 |
| Charle-Crespo, MÁ; Gomes-Carvalho, CS; Guerra-García, MM; Prejigueiro-Santás, A; Puga-Sarmiento, E; Rodríguez-Fernández, JB | 1 |
| Eisman, JA; Jönsson, B; Kanis, JA; Papaioannou, A; Siris, ES; Ström, O; Tosteson, A | 1 |
| Bachmeyer, C; Gauthier, M | 1 |
| Landfeldt, E; Lang, A; Robbins, S; Ström, O | 1 |
| Mosekilde, L; Pinholt, EM; Rejnmark, L; Schwartz, K; Vestergaard, P | 1 |
| Cooper, C; Cortet, B; Diaz-Curiel, M; Kanis, JA; Lorenc, RS; Reginster, JY; Rizzoli, R | 1 |
| Davey, DA | 1 |
| Jönsson, B; Kanis, JA; Ström, O | 1 |
| Huang, J; Kruse, M; Parthan, A; Taylor, D; Viswanathan, HN; Yurgin, N | 1 |
| Capaldo, A; Di Somma, C; Gimigliano, F; Iolascon, G; Menditto, E; Orlando, V | 1 |
| Hviid, A; Pasternak, B; Svanström, H | 1 |
| Reid, IR | 1 |
8 review(s) available for thiophenes and etidronate
| Article | Year |
|---|---|
Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Fractures, Bone; Humans; Middle Aged; Organometallic Compounds; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Thiophenes | 2005 |
How long should patients take medications for postmenopausal osteoporosis?
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Drug Administration Schedule; Drug Monitoring; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Risedronic Acid; Risk Assessment; Teriparatide; Thiophenes; Time Factors; Treatment Outcome | 2007 |
Pharmacological treatment of osteoporosis for people over 70.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Parathyroid Hormone; Risedronic Acid; Thiophenes; Vitamin D | 2007 |
Evidence based medicine and effective interventions of pharmacological therapy for the prevention of osteoporotic fractures.
Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Clodronic Acid; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Risedronic Acid; Selective Estrogen Receptor Modulators; Teriparatide; Thiophenes; Vitamin D | 2007 |
Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system.
Topics: Anthraquinones; Antirheumatic Agents; Calcitonin; Chondroitin Sulfates; Clinical Trials as Topic; Etidronic Acid; Glucosamine; Humans; Hyaluronic Acid; Organometallic Compounds; Osteoarthritis; Outcome Assessment, Health Care; Plant Extracts; Risedronic Acid; Thiophenes | 2008 |
Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
Topics: Alendronate; Bone Density Conservation Agents; Etidronic Acid; Fractures, Bone; Humans; Organometallic Compounds; Osteoporosis; Risedronic Acid; Teriparatide; Thiophenes | 2009 |
Effect of osteoporosis treatment on mortality: a meta-analysis.
Topics: Age Factors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Diphosphonates; Etidronic Acid; Fractures, Bone; Humans; Imidazoles; Organometallic Compounds; Osteoporosis; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Thiophenes; Treatment Outcome; Zoledronic Acid | 2010 |
Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF).
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Risedronic Acid; Thiophenes; Vitamin D | 2012 |
13 other study(ies) available for thiophenes and etidronate
| Article | Year |
|---|---|
Osteoporosis: non-hormonal treatment.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcitonin; Calcium, Dietary; Denosumab; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Thiophenes; Vitamin D; Women's Health | 2007 |
Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years.
Topics: Aged; Bone Density Conservation Agents; Cost-Benefit Analysis; Etidronic Acid; Female; Humans; Models, Statistical; Organometallic Compounds; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Risedronic Acid; Thiophenes | 2010 |
[Incidence of hip fractures due to osteoporosis in relation to the prescription of drugs for their prevention and treatment in Galicia, Spain].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Drug Prescriptions; Etidronic Acid; Female; Hip Fractures; Humans; Incidence; Male; Middle Aged; Organometallic Compounds; Osteoporotic Fractures; Retrospective Studies; Risedronic Acid; Spain; Thiophenes | 2011 |
Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cohort Studies; Cost-Benefit Analysis; Denosumab; Etidronic Acid; Female; Humans; Markov Chains; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Patient Compliance; Quality-Adjusted Life Years; RANK Ligand; Risedronic Acid; Thiophenes | 2011 |
How to prevent glucocorticoid-induced osteoporosis.
Topics: Bone Density Conservation Agents; Etidronic Acid; Glucocorticoids; Humans; Organometallic Compounds; Osteoporosis; Risedronic Acid; Thiophenes | 2010 |
Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; Etidronic Acid; Female; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Male; Medication Adherence; Middle Aged; Organometallic Compounds; Osteoporosis; Raloxifene Hydrochloride; Registries; Retrospective Studies; Risedronic Acid; Sweden; Thiophenes | 2011 |
Oral bisphosphonate use increases the risk for inflammatory jaw disease: a cohort study.
Topics: Administration, Oral; Aged; Alcoholism; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Case-Control Studies; Cohort Studies; Denmark; Diabetes Complications; Diphosphonates; Drug Therapy; Etidronic Acid; Female; Humans; Jaw Diseases; Male; Neoplasms; Organometallic Compounds; Osteitis; Osteomyelitis; Osteoporosis; Parathyroid Hormone; Periostitis; Radiotherapy; Raloxifene Hydrochloride; Risk Factors; Sjogren's Syndrome; Strontium; Thiophenes | 2012 |
Osteoporosis, osteopenia and fracture risk: widening the therapeutic horizons.
Topics: Adult; Age Factors; Aged; Algorithms; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Etidronic Acid; Female; Fractures, Bone; Hip Fractures; Humans; Male; Middle Aged; Organometallic Compounds; Osteoporosis; Risedronic Acid; Spinal Fractures; Thiophenes | 2012 |
Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Algorithms; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cost-Benefit Analysis; Denosumab; Drug Costs; Etidronic Acid; Female; Health Care Costs; Humans; Middle Aged; Models, Econometric; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Quality of Life; RANK Ligand; Risedronic Acid; Risk Assessment; Thiophenes; United Kingdom | 2013 |
Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cost-Benefit Analysis; Denosumab; Diphosphonates; Drug Costs; Etidronic Acid; Female; Health Care Costs; Humans; Insurance, Health, Reimbursement; Markov Chains; Osteoporosis, Postmenopausal; Risedronic Acid; Sweden; Thiophenes; United States | 2013 |
Osteoporosis drugs in real-world clinical practice: an analysis of persistence.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Substitution; Etidronic Acid; Female; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Retrospective Studies; Risedronic Acid; Thiophenes | 2013 |
Use of strontium ranelate and risk of acute coronary syndrome: cohort study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denmark; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Proportional Hazards Models; Risedronic Acid; Thiophenes | 2014 |
Efficacy, effectiveness and side effects of medications used to prevent fractures.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Hip Fractures; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Spinal Fractures; Teriparatide; Thiophenes; Treatment Outcome; Vitamin D; Zoledronic Acid | 2015 |